Work Package 8: Facilitation of the new screening approach implementation

WP 8

health tecnonolgy trasp

Facilitation

Hungary t
Belgium t

NKIP, Hungary, co-led by SCI, Belgium

Work Package Summary

The overall objective is to provide a comprehensive overview of the current state of art on lung, gastric and prostate cancer screening (ie, recently recommended screening) and inform their integration into current practice with screening for breast, cervical and colorectal cancers.

 

Specific objectives are as follows:

 

1) To design common data capture standards for personalised data within the recently recommended screening programs.

2) To facilitate development of the European data platforms for recently recommended screening programs in compliance with the EHDS principles.

3) To address pilot interventions in the areas with insufficient evidence to facilitate the goals of the recently recommended screening programs.

Task NrTask NameDescriptionParticipants
T8.1Support to methodology and harmonisation of data sets for lung cancer screening pilots1. Comprehensive and up-to-date information will be provided on guidance and
standards of organisation, processes, quality assurance, and data collection
management in LDCT lung cancer screening programmes; state-of-play in LDCT
lung cancer screening within EU MS and outside the EU; LDCT implementation
barriers in EU Member States, and on-going and future scientific developments
and unmet research needs.
2. Synergies and complementarity will be ensured through contributions to and
interactions with leaders and members of WP and tasks and working groups,
Health Authorities and other stakeholders with EU Member States and other
related EU Projects.
3. Advising on standardisation of cancer screening programmes and quality
assurance and data collection across the 6 established cancer entities covered
within this JA Consortium and future screening programmes in other cancer
entities.
4. Consult and help to facilitate the planning, set-up, and performance of
pilots and programmes aiming at implementation and improvement of LDCT lung
cancer screening and data collection projects within this JA Consortium and at
the levels of EU and its MS. Task 8.1 will build upon the substantial expertise and
experience and results and outputs of the EU4Health Consortium SOLACE on
the implementation of LDCT lung cancer screening, amongst others European a
Lung Cancer Screening Guideline with comprehensive Quality Assurance and
Data Parameter Set, State-of-Play and related Gap Analyses within EU Member
and EAA States, Findings from Implementation Projects, and Educational
Formats. The link to SOLACE will be achieved via their open-access Knowledge
Hub.
This task will be led by MSB, Germany, co-led by NKIP, Hungary.
LU
NKIP, SCI, ISPRO,
MoH SK, OIL,
PHC, RIVM, UZIS,
PMSI IO, SoS,
UHCZ, AUSLRE,
BIOSISTEMAK,
UZA, UT,
DYPEDE, VULSK,
LSMUKK, CHUSJ,
CHULN, NOI, CSF,
IACS, RCC, NCI,
MSB
T8.2Support to methodology and harmonisation of data sets of gastric cancer preventionTo ensure availability of common data registration approaches and creation of a
data platform for pooling data from previous and future gastric cancer prevention
studies, therefore, facilitating large data sets on implementation: a code-book will
be developed based on the source of ongoing projects such as EuroHelican and
TOGAS; an online data capture system will be developed, including a data
platform for Task 8.4; and data entry from previous and ongoing activities will be
piloted into the newly developed system. Either federated or centralised data
consolidation principles will be applied by ensuring that the obtained results are
compliant with the data standardisation principles, as detailed in WP5.
This task will be led by LU, Latvia.
LU
PMSI IO, UZIS,
NIJZ, IPOPORTO,
UT, NCI, MaR,
IACS, CFS,
LSMUKK,
T8.3Support to methodology and harmonisation of data sets of prostate cancer screening8.3.1. Capitalising on the knowledge and ongoing activities of the EU-funded project PRAISE U in the form of KPIs and PCa screening guidelines/ protocols
which are currently being developed for the PRAISE U pilot-sites, a PCa
screening working group will be formed and meet bimonthly to discuss key topics
and share knowledge and experience. MS will be encouraged and supported to
generate aggregated KPI data and collect and share data for in-depth analysis
and learning on an individually tailored risk-based screening algorithm. This will
be crucial for the further development of prostate cancer population-based
screening initiatives.
8.3.2. Sharing PRAISE-U knowledge with those MS that will most likely initiate
prostate cancer screening pilots within the coming years (SLO, SK, DE, IT).
Support additional to the screening work group activities, will be provided in the
form of setting up, Monitoring & Evaluation of their data infrastructure and data
collection. Such collaboration will enable collection of data from a considerable
number of MS on PCa screening initiatives without delay in data formatting etc.
This task will be led by EMC, Netherlands.
LU, ISPRO, TAI,
MoH SK, UZIS,
OIL,
EMC,
LoR, CPO,
AUSLRE, VULSK,
NOI, DKFZ, BIPS,
NNGYK, CSF,
RCC, IDIVAL,
IACS,
BIOSISTEMAK
T8.4Feasibility of H.pylori stool antigen testing (SAT) in combination with FIT-based colorectal cancer screening programsThe global experience of the potential of gastric cancer screening at the age of
>50 years, including by H.pylori SAT will be analyzed. Protocol for a study
combining FIT to SAT will be developed; relevant approvals, including from
ethical boards, will be secured; and initial pilot study will be conducted to address
feasibility of this approach in the EU. Altogether ≥1000 subjects will be invited to
participate in 4 centres in Europe. Invitations will be sent to individuals ≥50 years;
stool samples will be collected by the participants in home conditions and
delivered to a centralised laboratory. Those testing positive for H.pylori will get
invited to the study centre. Standardised survey questions will be used to collect
information on previous medical history and lifestyle factors; and offered H.pylori
eradication medication. One month after treatment, the effectiveness will be
tested by a C-urea breath test (UBT), and data on the potential adverse events
will be surveyed. A proportion of non-responders will be surveyed using a
telephone interview.
This task will be led by LU, Latvia.
LU
NKIP, TAI, INCa
IPOPORTO MaR,
IDIVAL, LSMUKK,
T8.5Integrating intensive smoking cessation with low-dose CTscreening
among heavy smokers
The following activities will be carried out to enable assessment of the concrete
effect of active cessation campaigns attached to LDCT-screening on smoking
prevalence and stage-specific lung cancer incidence among heavy-smokers, and
feasibility of these approaches and countries’ abilities to reach the target
population without existing registers of those who smoke:
1. Evaluation of the current-state-of art in smoking cessation interventions
attached to lung cancer screening in Europe (M1-24).
2. Scan of the spectrum of available, advanced methodologies and technology
for smoking cessation (M1-24).
3. Assessment of innovative strategies to reach the heavy-smoking screening
target population (M1-24).
4. Development of small-scale, randomised pilots (n=1200 2×600) in two
participating countries (Finland and Hungary) to evaluate whether active smoking
OIL, NKIP,
DoH IE, MoH SK,
CSF, RCSI, UZA,
HDH, IDIVAL,
Unicancer
AP-HP, NOI,
CHULN, CHUSJ

Task NrTask NameDescriptionParticipantsRoleIn-kind Contributions/Subcontracting
T8.1Support to methodology and harmonisation of data sets for lung cancer screening pilots1. Comprehensive and up-to-date information will be provided on guidance and
standards of organisation, processes, quality assurance, and data collection
management in LDCT lung cancer screening programmes; state-of-play in LDCT
lung cancer screening within EU MS and outside the EU; LDCT implementation
barriers in EU Member States, and on-going and future scientific developments
and unmet research needs.
2. Synergies and complementarity will be ensured through contributions to and
interactions with leaders and members of WP and tasks and working groups,
Health Authorities and other stakeholders with EU Member States and other
related EU Projects.
3. Advising on standardisation of cancer screening programmes and quality
assurance and data collection across the 6 established cancer entities covered
within this JA Consortium and future screening programmes in other cancer
entities.
4. Consult and help to facilitate the planning, set-up, and performance of
pilots and programmes aiming at implementation and improvement of LDCT lung
cancer screening and data collection projects within this JA Consortium and at
the levels of EU and its MS. Task 8.1 will build upon the substantial expertise and
experience and results and outputs of the EU4Health Consortium SOLACE on
the implementation of LDCT lung cancer screening, amongst others European a
Lung Cancer Screening Guideline with comprehensive Quality Assurance and
Data Parameter Set, State-of-Play and related Gap Analyses within EU Member
and EAA States, Findings from Implementation Projects, and Educational
Formats. The link to SOLACE will be achieved via their open-access Knowledge
Hub.
This task will be led by MSB, Germany, co-led by NKIP, Hungary.
LU
NKIP, SCI, ISPRO,
MoH SK, OIL,
PHC, RIVM, UZIS,
PMSI IO, SoS,
UHCZ, AUSLRE,
BIOSISTEMAK,
UZA, UT,
DYPEDE, VULSK,
LSMUKK, CHUSJ,
CHULN, NOI, CSF,
IACS, RCC, NCI,
MSB
COO
BEN
AE
AP
No
T8.2Support to methodology and harmonisation of data sets of gastric cancer preventionTo ensure availability of common data registration approaches and creation of a
data platform for pooling data from previous and future gastric cancer prevention
studies, therefore, facilitating large data sets on implementation: a code-book will
be developed based on the source of ongoing projects such as EuroHelican and
TOGAS; an online data capture system will be developed, including a data
platform for Task 8.4; and data entry from previous and ongoing activities will be
piloted into the newly developed system. Either federated or centralised data
consolidation principles will be applied by ensuring that the obtained results are
compliant with the data standardisation principles, as detailed in WP5.
This task will be led by LU, Latvia.
LU
PMSI IO, UZIS,
NIJZ, IPOPORTO,
UT, NCI, MaR,
IACS, CFS,
LSMUKK,
COO
BEN
AE
Yes (subcontracting)
T8.3Support to methodology and harmonisation of data sets of prostate cancer screening8.3.1. Capitalising on the knowledge and ongoing activities of the EU-funded project PRAISE U in the form of KPIs and PCa screening guidelines/ protocols
which are currently being developed for the PRAISE U pilot-sites, a PCa
screening working group will be formed and meet bimonthly to discuss key topics
and share knowledge and experience. MS will be encouraged and supported to
generate aggregated KPI data and collect and share data for in-depth analysis
and learning on an individually tailored risk-based screening algorithm. This will
be crucial for the further development of prostate cancer population-based
screening initiatives.
8.3.2. Sharing PRAISE-U knowledge with those MS that will most likely initiate
prostate cancer screening pilots within the coming years (SLO, SK, DE, IT).
Support additional to the screening work group activities, will be provided in the
form of setting up, Monitoring & Evaluation of their data infrastructure and data
collection. Such collaboration will enable collection of data from a considerable
number of MS on PCa screening initiatives without delay in data formatting etc.
This task will be led by EMC, Netherlands.
LU, ISPRO, TAI,
MoH SK, UZIS,
OIL,
EMC,
LoR, CPO,
AUSLRE, VULSK,
NOI, DKFZ, BIPS,
NNGYK, CSF,
RCC, IDIVAL,
IACS,
BIOSISTEMAK

COO

BEN
AE

No
T8.4Feasibility of H.pylori stool antigen testing (SAT) in combination with FIT-based colorectal cancer screening programsThe global experience of the potential of gastric cancer screening at the age of
>50 years, including by H.pylori SAT will be analyzed. Protocol for a study
combining FIT to SAT will be developed; relevant approvals, including from
ethical boards, will be secured; and initial pilot study will be conducted to address
feasibility of this approach in the EU. Altogether ≥1000 subjects will be invited to
participate in 4 centres in Europe. Invitations will be sent to individuals ≥50 years;
stool samples will be collected by the participants in home conditions and
delivered to a centralised laboratory. Those testing positive for H.pylori will get
invited to the study centre. Standardised survey questions will be used to collect
information on previous medical history and lifestyle factors; and offered H.pylori
eradication medication. One month after treatment, the effectiveness will be
tested by a C-urea breath test (UBT), and data on the potential adverse events
will be surveyed. A proportion of non-responders will be surveyed using a
telephone interview.
This task will be led by LU, Latvia.
LU
NKIP, TAI, INCa
IPOPORTO MaR,
IDIVAL, LSMUKK,
COO
BEN
AE
Yes (subcontracting)
T8.5Integrating intensive smoking cessation with low-dose CTscreening
among heavy smokers
The following activities will be carried out to enable assessment of the concrete
effect of active cessation campaigns attached to LDCT-screening on smoking
prevalence and stage-specific lung cancer incidence among heavy-smokers, and
feasibility of these approaches and countries’ abilities to reach the target
population without existing registers of those who smoke:
1. Evaluation of the current-state-of art in smoking cessation interventions
attached to lung cancer screening in Europe (M1-24).
2. Scan of the spectrum of available, advanced methodologies and technology
for smoking cessation (M1-24).
3. Assessment of innovative strategies to reach the heavy-smoking screening
target population (M1-24).
4. Development of small-scale, randomised pilots (n=1200 2×600) in two
participating countries (Finland and Hungary) to evaluate whether active smoking
OIL, NKIP,
DoH IE, MoH SK,
CSF, RCSI, UZA,
HDH, IDIVAL,
Unicancer
AP-HP, NOI,
CHULN, CHUSJ
BEN
AE
No

Subscribe to our newsletter to get news and updates.

Subscribe to our newsletter to get news and updates.

Logo EU EUCanScreen VerticalThe general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.

tiktok

FaceBook

X

Instagram

YouTube

LinkedIn

EUCanScreenLogo t

The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.

FaceBook

Twitter

Instagram

YouTube

LinkedIn

Logo EU

This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959

Print Friendly, PDF & Email
Μετάβαση στο περιεχόμενο